AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Ubrelvy (ubrogepant) is a prescription drug that’s used to treat migraine episodes. The drug comes as a tablet that you swallow. It’s usually taken as needed. Ubrelvy is prescribed for adults ...

Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.

Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big pharma stocks. Here's why they chose AbbVie(NYSE: ABBV), Amgen ...

Additionally, Nurtec, Ubrelvy (ubrogepant), and Zavzpret (zavegepant)—a nasal spray—are approved for acute treatment of migraine headaches. CGRP is a protein present in the trigeminal nerve, a cranial ...

As with other drugs, Ubrelvy (ubrogepant) can cause side effects, such as nausea and fatigue. Ubrelvy is not known to cause long-term side effects. Ubrelvy is a brand-name tablet prescribed for ...